SAN DIEGO, CA – February 10, 2024 - Antharis Therapeutics, a pioneering company dedicated to developing advanced monoclonal antibody-based therapies, is proud to announce its recent feature in The Silicon Review as a top emerging biopharmaceutical company. The article highlights Antharis’ innovative approach to creating new treatments for unmet medical needs, specifically focusing on its robust pipeline of next-generation monoclonal antibodies and antibody-drug conjugates (ADCs).
The article emphasizes Antharis’ commitment to leveraging state-of-the-art technologies and a multi-disciplinary scientific program to bring transformative therapies to market. Since its founding by Dr. Raphael Ribeiro-Pinaud, Antharis has distinguished itself through strategic acquisitions, collaborations, and a steadfast dedication to advancing precision medicine. These efforts underscore the company’s mission to provide cutting-edge treatments for patients facing serious health challenges, particularly in the realm of immuno-oncology.
“We are honored to be recognized by The Silicon Review as a leading emerging company in the biopharmaceutical sector. This recognition is a testament to the hard work of our dedicated team and our steadfast commitment to advancing therapies to address critical medical needs for patients in need.”, said Dr. Ribeiro-Pinaud, CEO & Chairman of Antharis Therapeutics.
To read the full article and learn more about Antharis Therapeutics’ vision and innovations, please visit The Silicon Review.
About Antharis Therapeutics
Founded in 2020, Antharis Therapeutics is at the forefront of monoclonal antibody drug development, aiming to address complex medical challenges through advanced therapeutic solutions. With a focus on immuno-oncology, Antharis combines cutting-edge science with strategic partnerships to develop a robust portfolio of innovative therapies that bring new hope to patients around the world.
